LLY

Lilly (Eli)

$1,240.34

-1.33% 2026-10-19

Health CareS&P 500

1M 3M 6M 1Y 2Y

LLYSPY

+4.9%

+7.6%

+8.3%

+35.3%

YTD

+16.0%

+55.5%

Grades vs sector

Momentum

70th pct in sector

12-1 return: +34.9%
Percentile within its GICS sector across the S&P 1500.

Growth

94th pct in sector

Revenue growth (YoY): +47.7%
Percentile within its GICS sector across the S&P 1500.

Value

18th pct in sector

Forward E/P: 3.8% · EBITDA/EV: 3.6%
Percentile within its GICS sector across the S&P 1500.

Profitability

96th pct in sector

A+

Profit margin: +33.5% · Return on equity: +102.3%
Percentile within its GICS sector across the S&P 1500.

Revisions

no data

–

EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Our models

Not held by any of our 3 live models right now.

Momentum Top 15

rank 56 of 499 · 12-1 momentum % 52.6

Quality Growth

not ranked (outside this model's universe or screens)

Momentum Blend

not in the current book

Key stats

Market cap–

P/E (trailing)–

P/E (forward)–

52-week range– – –

Revenue growth (YoY, latest qtr)–

Dividend yield–

Analyst consensus–

Mean price target–

Valuation & fundamentals

Bottom line

Leans undervalued

Model read-out from the numbers below, not advice. Score +2 (DCF counts double).

▲DCF (base case)above the price by 57%

•Piotroski F-score6/9

Discounted cash flow

Bear

$826

-33%

growth 18% · disc. 10.2% · term. 2.0%

Base

$1,946

+57%

growth 30% · disc. 9.2% · term. 2.5%

Bull

$3,755

+203%

growth 38% · disc. 8.2% · term. 3.0%

A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.

Reverse DCFfor context, not a signal

Not enough data to run a reverse DCF.

Edit assumptions · recalculates instantly

Your value per share–

Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.00 (n/a) × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.

Multiples vs Health Care

P/E (trailing)

sector median 29.9×

–

Forward P/E

sector median 17.6×

–

EV / EBITDA

sector median 15.8×

–

Price / sales

sector median 3.1×

–

Price / book

sector median 3.5×

–

FCF yield

sector median 4.1%

–

Quality & financial health

Gross margin

83.4%

Operating margin

–

FCF margin

35.3%

Net margin

33.5%

Return on equity

78.8%

Return on invested capital

–

Net debt / EBITDA

–

Current ratio

1.4×

Interest cover

–

Cash conversion (OCF/NI)

1.1×

Piotroski F-score 6/9 · last two fiscal years

✓ Positive net income✓ Positive operating cash flow✓ Return on assets improved✗ Cash flow above net income✗ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved

Analysts

No analyst targets available.

Annual history

FY	Revenue	Net income	Free cash flow
2025	$65.2B	$20.6B	$16.8B
2024	$45.0B	$10.6B	$8.8B
2023	$34.1B	$5.2B	$4.2B
2022	$28.5B	$6.2B	$7.6B
2021	$28.3B	$5.6B	$7.4B
2020	$24.5B	$6.2B	$6.5B

From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +31.7%.

Earnings

Next report: 2026-10-29 · before open · EPS est 7.11

EstimateActual (beat)Actual (miss)

Report	EPS est	Actual	Surprise
2026-08-05	6.58	8.38	+27.3%
2026-04-30	6.79	8.55	+25.9%
2026-02-04	6.91	7.54	+9.1%
2025-10-30	5.89	7.02	+19.1%
2025-08-07	5.59	6.31	+12.9%
2025-05-01	3.46	3.34	-3.4%
2025-02-06	5.07	5.32	+5.0%
2024-10-30	1.47	1.18	-19.5%

Quarterly revenue

Quarter	Revenue	YoY
2026-06-30	$23.0B	+47.7%
2026-03-31	$19.8B	–
2025-12-31	$19.3B	–
2025-09-30	$17.6B	–
2025-06-30	$15.6B	–

Recent dividends

2026-08-14: $1.730 · 2026-05-15: $1.730 · 2026-02-13: $1.730 · 2025-11-14: $1.500 · 2025-08-15: $1.500 · 2025-05-16: $1.500 · 2025-02-14: $1.500 · 2024-11-15: $1.300

Insider trades

Jonsson Patrik

EVP & President, LLY Int'l · 2026-08-17

SELL
$7.6M

Zakrowski Donald A

SVP, Finance, & CAO · 2026-08-10

SELL
$2.4M

Hakim Anat

EVP, GC & Secretary · 2026-08-07

SELL
$6.0M

None

None · None

SELL
–

None

None · None

SELL
–

None

None · None

SELL
–

None

None · None

SELL
–

None

None · None

SELL
–

None

None · None

SELL
–

None

None · None

SELL
–

None

None · None

SELL
–

None

None · None

SELL
–

News

Eli Lilly (LLY) Sees $85.4 Million in Net ETF Buying on Oct. 16

GuruFocus.com · 1h ago

Eli Lilly, IBD Stock Of The Day, Rides Foundayo, Medicare Bridge To Buy Point

Investor's Business Daily · 17h ago

Can Eli Lilly’s Growth Keep Justifying its Premium?

Insider Monkey · 22h ago

Has Johnson & Johnson Stock Become A Different Bet?

Trefis · 23h ago

Can Eli Lilly’s (LLY) Growth Machine Keep Delivering?

Insider Monkey · Oct 18

Moderna Stock Slumps, but It’s Too Early to Panic

Barrons.com · Oct 16

Stats refreshed 2026-10-19 19:02:53 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

coteau

Coteau Systematic StrategiesSystematic equity research and model portfolios.
Coteau Systematic Strategies publishes research, model portfolios and tools. It does not manage money or offer investment advice. Model results are hypothetical. Data: Yahoo Finance (delayed), SEC EDGAR.

What is Coteau?Disclaimer Terms Privacy Data status